Showing 44 RESULTS FOR
Brain disorder research
Lundbeck completes the acquisition of Alder BioPharmaceuticals - a company committed to transforming migraine treatment and prevention
Enhances Lundbeck’s leading portfolio of brain disease therapies with Alder’s highly complementary intravenous (IV) therapy for migraine prevention, eptinezumab
Futurecast: Exploring the New Era of Psychiatric Research
An update on new directions in psych research and the future of personalized medicine.
Lundbeck to Acquire Alder BioPharmaceuticals – a Company Committed to Transforming Migraine Treatment and Prevention – in a Transaction Valued at up to USD 1.95 Billion Net of Cash
Enhances Lundbeck’s leading portfolio of brain disease therapies with Alder’s highly complementary intravenous (IV) therapy for migraine prevention, eptinezumab
The Brain Foundation: How the Lundbeck Foundation is Shaping the Future of Brain Science
70% of Lundbeck is owned by the Lundbeck Foundation. What does the Foundation do, and what does it mean for Lundbeck, patients and brain research?
Welcome to the New Era of Alzheimer’s Research: How People with Alzheimer’s and Care Partners are Shaping the Future of Drug Development
Learn how John and Leigh, who live with Alzheimer’s, are partnering with Lundbeck and AD PACE to inject patient needs, preferences into R&D.